Stand Up To Cancer and Jazz Pharmaceuticals have entered into a three-year, $4 million research collaboration to research hard-to-treat cancers, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
